Cytokinetics · 16 hours ago
Intern – Medicinal Chemistry
South San Francisco, California
Internship
Onsite
Intern
$35/hr - $40/hrCytokinetics is a specialty cardiovascular biopharmaceutical company focused on advancing a pipeline of potential new medicines for patients with cardiac muscle dysfunction. They are seeking an intern to support a hit-to-lead medicinal chemistry project, contributing to the design, synthesis, and characterization of novel biologically active molecules.
BiopharmaBiotechnologyHealth Care
Responsibilities
Participate in the design, synthesis, purification, and characterization of novel biologically active molecules
Apply in-silico machine learning models to inform compound design
Contribute to exploratory research and lead optimization projects, and collaborate closely with colleagues in other groups
Summarize/interpret data and present findings in research meetings
Qualification
Required
Bachelor's degree in chemistry required
Prior synthetic organic chemistry lab experience strongly required
Demonstrated expertise in organic synthesis, chromatographic purification methods, and compound characterization using modern analytical techniques (NMR, MS, HPLC, etc.)
Organized, detail-oriented, excellent record-keeping skills, excellent verbal and written communication skills
Ability to work independently and perform well in a team environment
Preferred
Upcoming 3rd or 4th year PhD student preferred
Company
Cytokinetics
Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.
Founded in 1998
501-1000 employees
H1B Sponsorship
Cytokinetics has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (9)
2024 (9)
2023 (4)
2022 (6)
2021 (7)
2020 (4)
Funding
Current Stage
Public CompanyTotal Funding
$2.41BKey Investors
Royalty PharmaDeerfieldVulcan
2025-09-16Post Ipo Debt· $650M
2024-05-22Post Ipo Equity· $550M
2024-05-22Post Ipo Debt· $50M
Leadership Team
Robert Blum
President & CEO
Sung Lee
EVP & CFO
Recent News
GlobeNewswire
2026-01-13
Company data provided by crunchbase